Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 單克隆抗體
  4. F13A1 Monoclonal Antibody

F13A1 Monoclonal Antibody

  • 中文名稱：
    F13A1鼠單克隆抗體
  • 貨號：
    CSB-MA177758
  • 規(guī)格：
    ￥1320
  • 圖片：
    • IHC image of CSB-MA177758 diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-mouse IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    Through the use of immunization and hybridoma technology, an F13A1 monoclonal antibody was developed. To produce the antibody, B cells were extracted from the spleen of mice that were previously immunized with a synthesized peptide derived from human F13A1 and then fused with myeloma cells to create hybridomas. After screening and selecting, the F13A1-generating hybridomas were cultured in the mouse abdominal cavity. The F13A1 monoclonal antibody was purified from mouse ascites using affinity chromatography with specific immunogens. This purified F13A1 monoclonal antibody has been validated for use in ELISA and IHC applications.

    F13A1 plays a key role in the blood clotting process. It acts as a transglutaminase enzyme, which means it crosslinks fibrin (the main protein in blood clots) to make it stronger and more stable. F13A1 is synthesized and secreted by platelets and monocytes/macrophages, and it is activated by thrombin to carry out its function in the final stages of clot formation. In addition to its role in blood clotting, F13A1 has been implicated in other biological processes, including wound healing and bone remodeling.

  • Uniprot No.：
  • 基因名：
  • 別名：
    bA525O21.1 (coagulation factor XIII; A1 polypeptide) antibody; Coagulation factor XIII A chain antibody; Coagulation factor XIII A1 polypeptide antibody; Coagulation factor XIII A1 subunit antibody; Coagulation factor XIII; A polypeptide antibody; Coagulation factor XIIIa antibody; F13A antibody; F13A_HUMAN antibody; F13a1 antibody; Factor XIIIA antibody; Fibrin stabilizing factor; A subunit antibody; Fibrinoligase antibody; FSF; A subunit antibody; Protein glutamine gamma glutamyltransferase A chain antibody; Protein-glutamine gamma-glutamyltransferase A chain antibody; TGase antibody; Transglutaminase A chain antibody; Transglutaminase; plasma antibody; Transglutaminase. plasma antibody
  • 宿主：
    Mouse
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Synthesized peptide derived from human Factor XIIIa
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 抗體亞型：
    IgG2a, Kappa
  • 純化方式：
    The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, IHC
  • 推薦稀釋比：
    Application Recommended Dilution
    IHC 1:20-1:200
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能：
    Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin.
  • 基因功能參考文獻：
    1. Overall, genetically-determined FXIIIA levels have a significant long-term prognostic role, suggesting that a pharmacogenetics approach might help to select those AMI patients at risk of poor prognosis in the need of dedicated treatments. PMID: 30223472
    2. Inflammatory monocytes highly express Factor XIIIA, which promotes fibrin cross-linking to create a scaffold for lung squamous carcinomas cell invasion and metastases. PMID: 29777108
    3. Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients PMID: 29484525
    4. Coagulation factor FXIII-A (FXIIIA) was found to express specifically in the fetal beta islets but not in the alpha/delta islets. PMID: 29424810
    5. Factor XIIIa (AC-1A1) is a sensitive and specific nuclear marker for sebaceous differentiation...which can be utilized to aid in the diagnosis of sebaceous neoplasms. PMID: 28873247
    6. Our meta-analysis supports an association between F13A1 Val34Leu and recurrent pregnancy loss. PMID: 28683377
    7. A brief history of some key events in the conversion of fibrinogen to fibrin has been reviewed. (Review) PMID: 27519977
    8. The results of this study suggest that these biomarker F13A1 can serve as a potential non-invasive early diagnosis platform reflecting PiB-PET imaging for Mild Cognitive Impairment and Alzheimer's Disease. PMID: 27392853
    9. F13A1 gene mutations in 73 patients treated with recombinant FXIII-A2 PMID: 28520207
    10. Results show that the missense mutations-causing mild FXIII de fi ciency influence different aspects of FXIII function and can be functionally categorized on the basis of their expression phenotype. PMID: 27363989
    11. These findings provide insight into assembly of the fibrinogen/FXIII-A2B2 complex in both physiologic and therapeutic situations. PMID: 27561317
    12. FXIIIa exhibits a preference for Q237 in crosslinking reactions within fibrinogen alphaC (233-425) followed by Q328 and Q366. PMID: 26951791
    13. factor XIII Val34Leu polymorphism is associated with coronary artery diseases risk, especially myocardial infarction. Age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and diseases risk (Meta-Analysis) PMID: 27665853
    14. Mounting evidence now suggests that platelet FXIII-A modulates hemostasis by several different mechanisms. This condensed review discusses recent advances in the understanding of the novel intracellular and extracellular functions of platelet FXIII-A. [review] PMID: 27207415
    15. It is a unique case showing the combination of a highly aggressive angiosarcoma and presence of inherited FXIII deficiency. It is also a rare example demonstrating the benefit of FXIII genotyping besides the expected acquired FXIII deficiency possibly due to neoplasm induced increased consumption by elevated crosslinking of fibrin fibers. PMID: 26540128
    16. The Val34Leu polymorphism of FXIII was not found in Korean people, and compared with Caucasians, a noticeably low incidence of deep vein thrombosis was shown. PMID: 26802299
    17. Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients has been uncovered. PMID: 26852661
    18. Our meta-analysis suggests that there is no evidence for strong association between FXIII Val34Leu polymorphisms and intracerebral hemorrhage--{review} PMID: 26121426
    19. Deletion of 11 or more N-terminal amino acids disrupts intersubunit interactions, which may prevent FXIII-A2 homodimer formation. AP-FXIII plays an important role in the stability of the FXIII-A2 dimer. PMID: 26083359
    20. Mutations in the activation peptide of full-length recombinant FXIII regulate activation rates by thrombin, and V34L influences in vivo thrombus formation by increased cross-linking of the clot. PMID: 26743168
    21. Different FXIII-A dynamics and levels could be utilised as early prognostic indicators during acute MI, revealing the individual potential to heal and suggesting tailored treatments to avoid heart failure or its extreme consequence. PMID: 25947356
    22. FXIII Val34Leu polymorphism has a protective effect against recurrent spontaneous abortion. PMID: 25862345
    23. Report immunochromatographic test for detection of anti-factor XIII A subunit antibodies that can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII. PMID: 25740658
    24. These results indicate that FXIIIa activity can be modulated by fibrinolytic enzymes, and suggest that changes in fibrinolytic activity may influence cross-linking of blood proteins. PMID: 26359437
    25. Suggest that FXIIIa positive dermal dendrocytes may be the main antigen presenting cells in indeterminate leprosy. PMID: 25365500
    26. there is an evidence for association between factor XIII Val34Leu polymorphism and CSX PMID: 23677728
    27. These findings expose a newly recognized, essential role for fibrin crosslinking during whole blood clot formation and consolidation and establish FXIIIa activity as a key determinant of thrombus composition and size. PMID: 26324704
    28. Results show that FXIII-B Arg95 variant is associated with an increased risk of abdominal aortic aneurysms (AAA) suggesting a possible role for FXIII in AAA pathogenesis. PMID: 25384012
    29. The results demonstrate that FXIII-A Val34Leu polymorphism does not influence the occurrence of atherothrombotic ischemic stroke, but has an effect on the severity of its outcome. PMID: 24686102
    30. His343Gln was a novel missense mutation occurring in the core domain of the FXIII A subunit. This is the first report of genetically confirmed FXIII deficiency in Korea, with novel and recurrent F13A1 mutations. PMID: 25004025
    31. study suggested that FXIIIA Val34Leu polymorphism was a protective factor for myocardial infarction in caucasians PMID: 24042156
    32. Genotype 163TT of FXIII-A gene as a new independent risk factor for the development of Venous Thromboembolism in young women living in the North-West region of Russia. PMID: 26035561
    33. This study presents the covalent structure of single-stranded fibrin oligomers cross-linked by FXIIIa. PMID: 25896761
    34. a cohort of 27 individuals was analysed and four novel mutations leading to congenital FXIII deficiency were reported PMID: 24329762
    35. FXIII-A has a functional role through exposure on the activated platelet membrane where it exerts antifibrinolytic function by cross-linking alpha2AP to fibrin PMID: 25331118
    36. 8 new heterozygous missense mutations (Pro166Leu, Arg171Gln, His342Tyr, Gln415Arg, Leu529Pro, Gln601Lys, Arg703Gln and Arg715Gly) may affect catalysis, barrel domain integrity or activation peptide cleavage, depending on domain. PMID: 24889649
    37. results demonstrate the utility of eQTL mapping in the identification of novel asthma genes and provide evidence for the importance of FADS2, NAGA, and F13A1 in the pathogenesis of asthma. PMID: 24934276
    38. FXIII Val34Leu and PAI-1 4G/5G polymorphisms are prevalent in Egyptian women, with unexplained primary first trimester Recurrent miscarriage and combined polymorphisms statistically increasing the risk. PMID: 24702949
    39. FXIII-A serves as a preadipocyte-bound proliferation/differentiation switch that mediates effects of hepatocyte-produced circulating pFN. PMID: 24934257
    40. plasma FN assembly into bone matrix in vitro requires FXIIIA transglutaminase activity making pFN assembly an active, osteoblast-mediated process. PMID: 24246248
    41. this study presents for the first time an in depth and time-resolved analysis of the FXIIIa substrate proteome in plasma. PMID: 24443567
    42. Patients with advanced-stage NSCLC exhibited higher coagulation FXIII activity than healthy controls and early-stage NSCLC patients. PMID: 24142643
    43. These data suggest that plasma transglutaminase factor XIII may play a key role in fetal development of vertebrates via cross-link of Fas antigen. PMID: 24216108
    44. Data suggest that Factor XIII (composed of subunits F13A and F13B) increases rigidity/strength of fibrin clot, protects fibrin clot against shear stress in circulation, and protects fibrin from prompt elimination by fibrinolytic system. [REVIEW] PMID: 24476525
    45. Studies indicate that mutations in the factor XIII-A (FXIII-A) gene causing congenital factor XIII deficiency. PMID: 23929307
    46. Overproduction of FXIII-A by M2 macrophages might contribute to the excessive fibrin deposition in the submucosa of nasal polyps (NP), which might contribute to the tissue remodeling and pathogenesis of chronic rhinosinusitis with NP. PMID: 23541322
    47. The Fctor XIIIa R260C mutant has significantly altered conformations, resulting in the rapid degradation by the proteasome inside the synthesizing cells PMID: 23279035
    48. No association has been found between FXIII-A Val34Leu genotype and the risk for peripheral arterial disease in a Hungarian cohort of patients. PMID: 23518792
    49. The prevalence of a F13A1 gene intron 1 variant (IVS1+12C>A) was found with greater frequency in patients with a mild FXIII deficiency with no detectable F13A1 or F13 B mutations than in those with heterozygous F13A1 mutations or in normal controls. PMID: 23508224
    50. The results suggest an increase in FXIII activity as the number of repetitions of the short tandem repeat polymorphism in the F13A01 gene increased up to allele 5. PMID: 22909824

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Factor XIII subunit A deficiency (FA13AD)
  • 亞細胞定位：
    Cytoplasm. Secreted. Note=Secreted into the blood plasma. Cytoplasmic in most tissues, but also secreted in the blood plasma.
  • 蛋白家族：
    Transglutaminase superfamily, Transglutaminase family
  • 數(shù)據(jù)庫鏈接：

    HGNC: 3531

    OMIM: 134570

    KEGG: hsa:2162

    STRING: 9606.ENSP00000264870

    UniGene: Hs.335513